(Q44992882)

English

Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01). (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

neuropsychology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Alzheimer's disease

1 reference

based on heuristic

inferred from title

Paulo Caramelli

1

object named as

Paulo Caramelli

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

Márcia L F Chaves

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Eliasz Engelhardt

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

João Carlos B Machado

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Rodrigo R Schultz

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Francisco A C Vale

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Helenice Charchat-Fichman

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Brazilian Multi-Center Galantamine Study (GAL-BRA-01)

8

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

1 June 2004

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Arquivos de Neuro-Psiquiatria

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

2B

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

379-384

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Epidemiologic survey of dementia in a community-dwelling Brazilian population

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Attention and executive deficits in Alzheimer's disease. A critical review

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

A post-mortem study of the cholinergic and GABA systems in senile dementia.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Cholinergic deficits contribute to behavioral disturbance in patients with dementia

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Muscarinic versus nicotinic modulation of a visual task. a pet study using drug probes

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2004000300001

21 January 2018

Identifiers

10.1590/S0004-282X2004000300001

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44992882&oldid=1521681052"